Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The EMA's safety committee is reviewing all injectable iron formulations after reports of severe low phosphate levels and bone-softening disease — even in patients with no known risk factors. The spotlight is on ferric carboxymaltose, which shows a dramatically higher rate of hypophosphatemia than alternatives. Regulators may update prescribing rules or require enhanced monitoring across the entire drug class.
Europe's drug safety watchdog is taking a hard look at injectable iron medicines after a wave of concerning reports. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has launched a class-wide safety review following cases of severe hypophosphatemia — dangerously low blood phosphate — and osteomalacia (bone softening) linked to these treatments, including after just one or two doses and in patients with no pre-existing risk factors.
Injectable iron is widely used when oral supplements aren't enough — think dialysis patients, surgical candidates, heart failure patients, and pregnant women with severe deficiency. The problem? Low phosphate symptoms like fatigue, muscle pain, and bone pain can easily be mistaken for the iron deficiency itself, making diagnosis tricky. And osteomalacia may not even show up on standard X-rays, adding another layer of diagnostic difficulty.
By the Numbers:
Why it matters: PRAC's review could lead to updated prescribing labels, stricter monitoring requirements, or new risk-minimization measures across all injectable iron products in the EU — with real implications for how clinicians manage iron deficiency treatment going forward.
